Adarx Pharmaceuticals Inc., a late-stage developer of gene therapies, raised $446.3 million in an upsized initial public offering that priced at the top of its marketed range.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.